The detection and significance of minimal residual disease in chronic myeloid leukemia

Medicina

Volumn 60, Issue SUPPL. 2, 2000, Pages 66-70

  Radich, Jerald P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Chronic myeloid leukemia; M nimal residual disease

Indexed keywords

BCR ABL PROTEIN; TUMOR MARKER;

BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; GENETICS; HUMAN; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REMISSION; REVIEW; RISK FACTOR; TIME;

BONE MARROW TRANSPLANTATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034568023     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Heisterkamp N, Jenkins R, Thibodeau S, Testa JR, Weinberg K, Groffen J. The bcr gene in Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 1989; 73: 1307-11.
2. De Klein A, Hagemeijer A, Bartram CR, et al. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369-75.
3. Chan LC, Karhi KK, Rayter SI, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblatic leukaemia. Nature 1987; 325: 635-7.
4. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035-42.
5. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987; 235: 85-8.
6. Saiki PK, Gelfand DH, Stoeffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-90.
7. Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci 1988, 85: 5698-702.
8. Hughes TP, Morgan GJ, Martial P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of the polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-8.
9. Roth MS, Antin JH, Ash R, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after an allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992; 79: 276-82.
10. Miyamura K, Tahara T, Tanimoto M, et al. Long perisitent bcl-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients. Blood 1993; 81: 1089-94.
11. Radich JP, Gehly G, Gooley T, et al. PCR detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632-8.
12. Pichert G, Roy DC, Goin Ret al. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncology 1995; 13: 1704-13.
13. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation of chronic myeloid leukemia. Bone Marrow Transplantation 1996; 17: 643-7.
14. Lin F, van Rhee F, Goldman JM, Cross NCP. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-8.
15. Costello RT, Kirk J, Gabert J. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leukemia and Lymphoma 1996; 20: 239-43.
16. van Rhee F, Lin F, Cross NCP, et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1994; 14: 609-12.
17. Radich J, Gooley T, Bryant E, Flowers MED, Clift R. The significance of bcr-abl "molecular relapse" in CML patients ≥ 18 months post-transplant. Blood 1999; 94: 625.
18. Cross NCP, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-36.
19. Lion T, Gaiger A, Henn T, et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995; 9: 1353-60.
20. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
21. 18 (q32; q21) in patients with folicular lymphoma. Am J Pathol 1998; 153: 63-8.
22. Branford S, Hughes TP, Rudzski Z. Monitoring chronic myeloid leukemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Brit J Haematol 1999; 107: 587-99.
23. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukaemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia 1999; 13: 957-64.
24. Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Brit J Haematol 1998; 102:768-74.
25. Maruyama F, Stass SA, Estey EH, et al. Detection of AML1/ ETO fusion transcript as a tool for diagnosing t (8; 21) positive acute myelogenous leukemia. Leukemia 1994; 8: 40-5.
26. Kusec R, Laczika K, Knobl P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t (8; 21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735-9.
27. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DS, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336: 317-23.
28. Vora A, Frost L, Goodeve A, et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998; 92: 2334-7.
29. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. Bcl2 translocation frequency rises with age. Proc Natl Acad Sci 1994; 91: 8910-4.
30. H translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. Cancer Res 1995; 55: 2876-82.
31. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-22.
32. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-7.
33. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics 1996; 14: 457-60.
34. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer. Class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-7.
35. Alizadeh AA, Eisen MC, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.